This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Day One Biopharmaceuticals Stock (NASDAQ:DAWN) Get DAWN alerts:Sign Up Key Stats Today's Range$21.49▼$21.5350-Day Range$10.03▼$21.5352-Week Range$5.64▼$21.53Volume2.99 million shsAverage Volume1.52 million shsMarket Capitalization$2.22 billionP/E RatioN/ADividend YieldN/APrice Target$23.29Consensus RatingHold Company Overview Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit. The company’s pipeline includes several small-molecule candidates in various stages of development. The lead program, D1-B701, is a selective FGFR4 inhibitor designed to treat FGF19-driven hepatocellular carcinoma and other solid tumors. Additional programs include D1-H201, a selective HDAC6 inhibitor for certain hematologic malignancies, and D1-R199, a RET kinase inhibitor targeting RET fusion-positive cancers. Each program is supported by companion diagnostic strategies aimed at enriching patient populations and optimizing clinical outcomes. Founded in 2017, Day One Biopharmaceuticals is headquartered in San Diego, California, and maintains research and development operations in both the United States and Asia. The company’s leadership team comprises professionals with extensive experience in oncology drug discovery, clinical development, regulatory affairs and commercial strategy. Day One collaborates with academic and industry partners to advance its pipeline and remains committed to addressing significant unmet needs in cancer therapeutics through scientifically rigorous and patient-focused innovation.AI Generated. May Contain Errors. Read More Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DAWN Stock News HeadlinesDAWN Share News TodayJuly 8, 2026 | uk.investing.comJonesTrading Sticks to Its Hold Rating for Day One Biopharmaceuticals (DAWN)April 23, 2026 | theglobeandmail.com60 years. Zero competitors.One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 times global electricity demand - with zero competition. Last year, their crew drilled in 16 days what the government projected would take 64. Now Google has a 15-year deal locked in, Bill Gates has committed $100 million, and the Pentagon has made it a top priority. On August 18th, a new Washington policy adds another advantage rivals cannot match.July 28 at 1:00 AM | Behind the Markets (Ad)Servier completes the acquisition of Day One BiopharmaceuticalsApril 23, 2026 | prnewswire.comDay One Biopharmaceuticals, Inc.April 3, 2026 | edition.cnn.comDay One Biopharmaceuticals (DAWN) price target decreased by 10.27% to 21.16March 27, 2026 | msn.comDay One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWNMarch 26, 2026 | businesswire.comServier to Acquire Day One Biopharmaceuticals in MergerMarch 14, 2026 | theglobeandmail.comSee More Headlines DAWN Stock Analysis - Frequently Asked Questions How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) released its quarterly earnings data on Tuesday, February, 24th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.04. The firm earned $53.72 million during the quarter, compared to the consensus estimate of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative trailing twelve-month return on equity of 23.43%. Read the conference call transcript. When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $150 million in an initial public offering (IPO) on Wednesday, May 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Day One Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Day One Biopharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Tesla (TSLA). Company Calendar Last Earnings2/24/2026Today7/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 DAWN's financial health is in the Green zone, according to TradeSmith. DAWN has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DAWN CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees60Year Founded2018Price Target and Rating Average Price Target for Day One Biopharmaceuticals$23.29 High Price Target$34.00 Low Price Target$17.00 Potential Upside/Downside+8.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$107.32 million Net Margins-67.85% Pretax Margin-69.10% Return on Equity-23.43% Return on Assets-20.69% Debt Debt-to-Equity RatioN/A Current Ratio8.02 Quick Ratio7.91 Sales & Book Value Annual Sales$158.18 million Price / Sales14.06 Cash FlowN/A Price / Cash FlowN/A Book Value$4.30 per share Price / Book5.01Miscellaneous Outstanding Shares103,330,000Free Float96,927,000Market Cap$2.22 billion OptionableOptionable Beta-1.74 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:DAWN) was last updated on 7/28/2026 by MarketBeat.com Staff. From Our PartnersMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredA 50-year dollar arrangement just ended - what it means for youIn 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a litt...Golden Portfolio | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | Sponsored60 years. Zero competitors.One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...Behind the Markets | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWhat Elon told his top shareholders in TexasLate last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...Banyan Hill Publishing | SponsoredTrump’s emergency dollar resetBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
